Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
215.77
-5.12 (-2.32%)
Aug 11, 2026, 4:00 PM EDT - Market closed
Axsome Therapeutics Employees
Axsome Therapeutics had 1,220 employees as of March 31, 2026. The number of employees increased by 508 or 71.35% compared to the same quarter last year.
Employees
1,220
Change
508
Growth
71.35%
Revenue / Employee
$636,532
Profits / Employee
-$157,085
Market Cap
11.30B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 1,220 | 508 | 71.35% |
| Dec 31, 2025 | 925 | 242 | 35.43% |
| Sep 30, 2025 | 816 | 209 | 34.43% |
| Jun 30, 2025 | 846 | 257 | 43.63% |
| Mar 31, 2025 | 712 | 143 | 25.13% |
| Dec 31, 2024 | 683 | 138 | 25.32% |
| Sep 30, 2024 | 607 | 105 | 20.92% |
| Jun 30, 2024 | 589 | 167 | 39.57% |
| Mar 31, 2024 | 569 | 176 | 44.78% |
| Dec 31, 2023 | 545 | 162 | 42.30% |
| Sep 30, 2023 | 502 | 150 | 42.61% |
| Jun 30, 2023 | 422 | 224 | 113.13% |
| Mar 31, 2023 | 393 | 277 | 238.79% |
| Dec 31, 2022 | 383 | 275 | 254.63% |
| Sep 30, 2022 | 352 | 246 | 232.08% |
| Jun 30, 2022 | 198 | 105 | 112.90% |
| Mar 31, 2022 | 116 | 46 | 65.71% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| Exelixis | 1,077 |
| Madrigal Pharmaceuticals | 915 |
| Corcept Therapeutics | 730 |
| Arrowhead Pharmaceuticals | 711 |
| Cytokinetics | 673 |
| Halozyme Therapeutics | 423 |
| Summit Therapeutics | 265 |
AXSM News
- 21 hours ago - Axsome Therapeutics price target lowered to $297 from $304 at RBC Capital - TheFly
- 23 hours ago - Axsome Therapeutics price target raised to $251 from $242 at Morgan Stanley - TheFly
- 1 day ago - Axsome Therapeutics price target raised to $275 from $260 at Guggenheim - TheFly
- 1 day ago - Axsome Therapeutics price target raised to $256 from $255 at Wells Fargo - TheFly
- 1 day ago - Axsome Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 1 day ago - Axsome Therapeutics Earnings release: Q2 2026 - Filings
- 1 day ago - Axsome Therapeutics Slides: Q2 2026 - Filings
- 1 day ago - Axsome Therapeutics Quarterly report: Q2 2026 - Filings